Adrenal scintiscanning with NP-59, a new radioiodinated cholesterol agent

Adrenal imaging in the past has been limited in its clinical application by the long interval between administration of dose and visualization of adrenal glands. We review our experience with the use of a newer labeling agent, NP-59, in 29 patients with various adrenal disorders and in 4 normal subjects. With this agent, identification of adrenal lesions is possible with a high degree of accuracy, and diagnostic information is usually available within 48 hours. NP-59 is particularly useful in evaluating primary aldosteronism and selected cases of Cushing's syndrome.